Aim: Early life stress can induce epigenetic changes through genetic and environmental interactions and is a risk factor for depression. Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of depression and antidepressant drug action. We investigated epigenetic changes at the BDNF exon I promoter in the hippocampus of adult rats subjected to maternal separation (MS) during early life and treated with an antidepressant drug as adults.
and methylation). 9, 10 Methylation of cytosine-phos phate-guanine (CpG) dinucleotides in promoter regions generally represses gene transcription. This effect is mediated by a family of methyl-binding proteins that bind to methylated CpG sites. A member of the methyl-binding protein family, methyl CpG-binding protein 2 (MeCP2), functions as a transcriptional repressor through its interactions with corepressors and chromatin-remodeling factors. 11, 12 DNA methylation is catalyzed by DNA methyltransferases (DNMT): DNMT1 plays a role in maintaining methylation patterns during DNA replication, whereas DNMT3a and DNMT3b are involved in de novo methylation of unmethylated DNA. 13, 14 Histone acetylation is associated with active transcription, whereas histone methylation is associated with both transcriptional activation and repression, depending on the residue and valence state of the methylation. 15, 16 Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of depression and antidepressant drug action. A previous study found that BDNF levels were decreased in the serum of human patients with depression, and that protein levels were normalized by antidepressant drugs. 17 Furthermore, decreased BDNF expression was observed in rodent models of stress. 18, 19 In rodents, BDNF is upregulated by chronic antidepressant drug treatment. 20 Infusion of BDNF into the hippocampus produces an antidepressant-like effect in animal models of depression, 21 and conversely, a reduction in BDNF expression results in depressionlike behavior in animals. 22 The rodent BDNF gene contains eight 5 0 -noncoding exons and one 3 0 -coding exon, each of which can be alternatively spliced to a common coding exon to generate several mRNA transcripts, all encoding the same BDNF protein. 23 Increased methylation of the BDNF exon I promoter has been detected in the blood of patients with depression. 24, 25 Moreover, patients with depressive disorder who remitted under electroconvulsive therapy had lower methylation rates of the BDNF exon I promoter than did non-remitters. 26 Maternal separation (MS) during the early postnatal period is the most widely used rodent model of ELS, and increasing evidence suggests that MS results in epigenetic changes in rodents. 27 For instance, early MS is associated with altered DNA methylation of genes involved in depression, stress, plasticity, and emotion, including BDNF (exon IV and IX promoters), 28 glucocorticoid receptor (exon I 7 promoter), 29 corticotrophin-releasing hormone (promoter), 30 and arginine vasopressin (AVP enhancer). 31 Because most ELS research has focused on DNA methylation, few studies have investigated the effects of ELS on histone acetylation. A previous study in a rodent model of early-life maltreatment found that histone H3 acetylation at the BDNF promoter IV was decreased in the adult medial prefrontal cortex of maltreated rats, whereas no alterations were found at the BDNF promoter I. 32 We previously reported a reduction in histone acetylation at the BDNF exon IV promoter in the hippocampus of adult rats exposed to MS. 33 No studies have investigated histone acetylation at the BDNF exon I promoter after exposure to MS, although the DNA methylation profiles of this promoter region have been examined in depression. Furthermore, few studies have investigated whether specific epigenetic modifications induced by MS can be regulated by antidepressant drug treatment. Our previous study found that MS caused alterations in histone acetylation at the BDNF exon IV promoter in the rat hippocampus, which were reversed by chronic escitalopram (ESC) treatment. 33 We examined whether histone H3 acetylation and MeCP2 binding to the BDNF exon I promoter were altered in the hippocampus of adult rats subjected to the ELS of MS. Furthermore, we investigated whether MS affected the expression of DNMT1 and DNMT3a, genes that are important for regulation of epigenetic patterns in the hippocampus. To determine whether antidepressant drugs can prevent these epigenetic changes, rat pups were chronically treated with ESC as adults.
METHODS Animals
Pregnant female Sprague-Dawley rats were purchased from Orient Bio (Gyeonggi-Do, South Korea) on gestation day 15. All experiments involving animals were approved by the Committee for Animal Experimentation and the Institutional Animal Laboratory Review Board of Inje Medical College (approval no. 2013-034). All animals were maintained under standard laboratory conditions (21 C, 12/12-h light/dark cycle, food and water ad libitum). Pregnant females were individually housed with sawdust until delivery.
Experimental design
Male rats were divided into four groups (12 rats per group) as follows: (i) the Control group (nonseparated rats receiving vehicle [1 mL/kg]); (ii) the Control + ESC group (non-separated rats receiving ESC [10 mg/kg]); (iii) the MS group (MS rats receiving vehicle); and (iv) the MS + ESC group (MS rats receiving ESC). The rats were treated with ESC daily for 3 weeks once they reached adulthood (postnatal day [PND] 56). ESC oxalate (obtained as a generous gift from Sandoz, UK) was mixed fresh daily, dissolved in vehicle (0.7% glacial acetic acid in 0.9% saline), and administered intraperitoneally to the animals. The 10-mg/kg ESC dose was selected based on a previous study showing that this dose exerted antidepressant-like effects on behavior induced by chronic mild stress. 34 Moreover, this dose has been shown to improve MS-induced neurochemical alterations in the rat hippocampus. 35 
MS protocol
The MS protocol was performed as described previously. 33 Briefly, rat pups were separated from their mothers for 3 h daily from PND 1 to PND 21. During separation, mothers and pups were placed in separate cages. The pups were then returned to their home cage and cared for by their mothers.
Measurement of BDNF protein levels
Hippocampal tissue samples were homogenized in lysis buffer (protein extraction solution , ELPIS Biotech, Daejeon, Korea) and centrifuged at 13 600 g for 15 min at 4 C. The supernatant was collected, and the total protein concentration was determined according to the Bio-Rad Protein Assay (Bio-Rad, Milan, Italy) procedure. The protein concentration of the sample was adjusted to 20 μg in a sample volume of 100 μL. BDNF protein levels were measured by enzyme-linked immunosorbent assay (ELISA) using the BDNF Emax Immunoassay System according to the manufacturer's instructions (Promega, Madison, WI, USA). Briefly, 96-well plates were coated with an anti-BDNF monoclonal antibody and incubated at 4 C overnight. The plates were incubated with blocking and sample buffer for 1 h at room temperature. Samples prepared as described above were transferred to the anti-BDNF-coated ELISA plate. BDNF levels were normalized to the total amount of protein in the sample.
Measurement of mRNA levels by quantitative reverse-transcription polymerase chain reaction
Total RNA was extracted from the hippocampus using Trizol reagent (Invitrogen, Carlsbad, CA, USA) as described previously. 33 One microgram of total RNA was reverse transcribed into cDNA using the amfiRivertII cDNA synthesis master mix (GenDepot, Baker, TX, USA). Briefly, template cDNA was mixed with SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The polymerase chain reaction (PCR) program, in the CFX96 real-time PCR detection system (Bio-Rad), was as follows: one cycle of 95 C for 3 min, followed by 45 cycles of 95 C for 35 s, 50 C (BDNF exon I), or 60 C (DNMT1 and DNMT3a) for 35 s, and 72 C for 35 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene. The quantitative reversetranscription (qRT)-PCR analyses for BDNF exon I, DNMT1, DNMT 3a, and GAPDH were performed using the following primers: BDNF exon I:
0 . The ΔCt value was calculated using the formula, ΔCt = Ct target gene -Ct GAPDH , and the fold difference relative to the control group was quantified using the 2 −55Ct method.
Chromatin immunoprecipitation assays
As described previously, 33 hippocampal tissue samples were cross-linked, homogenized, and sonicated to generate 200-500-bp chromatin fragments. The chromatin lysate (10 μg) was incubated with an antibody against acetyl-histone H3 (K9/K14, 06-599; Millipore, Billerica, MA, USA) or MeCP2 (ab2828; Abcam, Cambridge, UK).
Protein-associated chromatin was extracted in phenol/chloroform (Amresco, Solon, OH, USA) and precipitated in ethanol (Merck, Hunterdon, NJ, USA) prior to real-time PCR analysis. Briefly, the purified DNA was subjected to PCR amplification, with each sample run in duplicate using 2-μL DNA eluate per reaction. Samples were mixed with SYBR Green Supermix (Bio-Rad). The program for PCR was as follows: one cycle of 95 C for 3 min, followed by 45 cycles of 95 C for 35 s, 50 C for 35 s, and 72 C for 35 s in the CFX96 real-time PCR detection system. The following primers were used to amplify the BDNF exon I promoter: forward 5 0 -GATCATCACTCACGACCACG-3 0 and reverse 5 0 -CAGCCTCTCTGAGCCAGTTACG-3 0 . The chromatin immunoprecipitation (ChIP) results were normalized to the input DNA. The ΔCt value was calculated using the formula, ΔCt = Ct ip − Ct input , and the fold difference relative to the control group was quantified using the 2 −55ct method.
Statistical analysis
All statistical analyses were performed using GraphPad Prism software (ver. 7.0; GraphPad Software, La Jolla, CA, USA Fig. 1a ), suggesting that ESC prevented the MS-induced decrease in BDNF.
We found significant effects of MS and ESC on BDNF exon I mRNA levels in the hippocampus (MS: F(1, 44) = 4.634, P = 0.037; ESC: F(1, 44) = 7.376, P = 0.010) but no interaction between the two factors (F(1, 44) = 1.498, P = 0.228). Tukey's multiple comparison test revealed a tendency toward a decrease in BDNF exon I mRNA levels in the MS group compared with the Control group (Control vs MS group: 1.00 AE 0.11 vs 0.76 AE 0.10, P = 0.080). ESC treatment increased BDNF exon I mRNA levels after MS (MS vs MS + ESC group: 0.76 AE 0.10 vs 1.06 AE 0.12, P = 0.002, Fig. 1b ).
Effects on histone H3 acetylation levels and MeCP2 binding to the BDNF exon I promoter
ChIP followed by real-time PCR was performed to measure acetylated histone H3 levels and MeCP2 binding to the BDNF exon I promoter in the hippocampus.
Similar to the BDNF exon I mRNA findings, twoway ANOVA of histone H3 acetylation revealed significant effects of MS, F(1, 44) = 8.414, P = 0.006, and ESC, F(1, 44) = 17.940, P < 0.001, but no interaction between MS and ESC, F(1, 44) = 1.941, P = 0.171. The post-hoc analysis revealed that acetylated H3 levels were reduced in the MS group compared with the Control group (Control vs MS group: 1.00 AE 0.05 vs 0.84 AE 0.04, P = 0.020) and were significantly higher in the MS + ESC group than in the MS group (MS vs MS + ESC group: 0.84 AE 0.04 vs 1.06 AE 0.07, P = 0.001; Fig. 2a) . Figure 2b shows the effects of MS and ESC on MeCP2 binding to the BDNF exon I promoter. Twoway ANOVA revealed a significant effect of ESC on MeCP2 levels, F(1, 44) = 11.040, P = 0.002, but no effect of MS, F(1, 44) = 1.414, P = 0.241, or interaction between MS and ESC, F(1, 44) = 2.579, P = 0.115. Moreover, the post-hoc analysis did not reveal a significant difference between the Control and MS groups (P = 0.210). However, ESC treatment significantly decreased MeCP2 binding in MS rats (MS vs MS + ESC group: 1.14 AE 0.04 vs 0.90 AE 0.08, P = 0.006).
Effects on DNMT mRNA levels in the hippocampus
To further assess the effects of MS and ESC on DNMT, epigenetic regulators, we measured DNMT1 and DNMT3a mRNA levels in the hippocampus. . Once they reached adulthood (PND 56), the rats were injected with ESC (10 mg/kg) or vehicle (VEH; 1 mL/kg, 0.9% saline) for 21 days (n = 12 animals/group). Chromatin immunoprecipitation assays were performed to measure the levels of (a) acetylated histone H3 and (b) MeCP2 binding to the BDNF exon I promoter in the hippocampus. CON, non-separated rats with or without ESC; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PMS, MS rats with or without ESC. Data are expressed as means AE standard error of the mean. *P < 0.05 vs control group; † † P < 0.01 vs MS group.
DISCUSSION
We found that exposure to MS for 3 weeks resulted in downregulation of BDNF protein and exon I mRNA and induced epigenetic changes at the BDNF exon I promoter in the hippocampus of adult rats. We further showed that chronic ESC treatment in adult rats prevented the epigenetic effects induced by postnatal MS. MS can cause persistent depression-like behavior and neuroendocrine, structural, and molecular changes in the adult brain. A previous study found that MS-induced anxiety in the novelty-suppressed feeding test and MS-induced depression-like behavior in the forced swimming and sucrose preference tests were caused by an increased hypothalamicpituitary-adrenal (HPA) axis response to stress. 36 Furthermore, MS triggers several structural changes in the hippocampus, including neurogenesis, 37 dendritic length, and dendritic spine density. 38 The structural changes induced by MS are believed to be accompanied by altered expression of BDNF, which is involved in neurogenesis, 39 neural survival, 40 synaptogenesis, 41 and synaptic plasticity 42 in the brain.
Our finding that MS reduced BDNF protein levels is consistent with a previous study showing that MS (3 h daily from PND 2 to PND 14) resulted in abnormal levels of mature BDNF in the hippocampus. 43 However, that study did not investigate which BDNF transcripts were involved in the MS-induced alterations. BDNF transcription is complex, as the gene contains at least eight alternative promoters, which are differentially regulated by several cisregulatory elements that control BDNF expression in different brain regions. 23 We previously reported reduced expression of BDNF total and exon IV mRNA in rats subjected to MS. 33 Our finding that MS downregulated the expression of BDNF exon I suggests that changes observed in BDNF protein levels are dependent on the modulation of exon I as well as exon IV. Based on these findings, we hypothesized that MS modulates the epigenetic mechanisms underlying the regulation of BDNF exon I. We found that MS decreased histone H3 acetylation levels at the exon I promoter. A previous investigation of epigenetic regulation of the BDNF gene found that miR-16, a candidate miRNA regulating BDNF, was associated with the epigenetic mechanism mediating the influence of maternal deprivation on BDNF expression in the hippocampus. 44 Moreover, other animal studies have found an interaction between a stressful environment and histone acetylation associated with BDNF. For example, acute immobilization stress has been reported to influence the H3 acetylation levels at the promoters of exons I, IV, and VI, 45 and prenatal exposure to methyl mercury has been shown to decrease H3 acetylation at the exon IV promoter. 46 The present study investigated alterations in the whole hippocampus of adult rats. Notably, some epigenetic modification patterns in the whole hippocampus differed from those in specific subregions. For example, DNA methylation at the BDNF exon IV promoter site in the dorsal CA1 region has been observed in response to psychosocial stress via predator exposure; however, no changes were observed in the dorsal dentate gyrus or dorsal CA3. 47 Additionally, alterations in histone H3 methylation induced by acute restraint stress have been found in the dentate gyrus and CA1, but not CA3. This suggests that subregions of the hippocampus respond differently to various stresses. 48 Antidepressant drugs reverse the stress-induced behavioral or neurogenic alterations associated with histone modifications of BDNF. Chronic imipramine treatment reversed social avoidance behavior after chronic defeat stress and induced long-lasting H3 hyperacetylation at the BDNF exon III and IV promoters in defeated mice. 49 Chronic amitriptyline treatment attenuated repressive histone methylation at the BDNF exon IV promoter, decreased neurogenesis, and reduced memory deficits in rats subjected to MS. 50 Our study focused on ESC, a selective serotonin reuptake inhibitor (SSRI). We found that chronic ESC treatment ameliorated changes in histone acetylation at the BDNF exon I promoter in MS rats. Previous studies have shown that ESC treatment improves depression-like behavior and memory deficits caused by early MS. 51, 52 Thus, ESC may prevent the behavioral abnormalities associated with MS via epigenetic modulation of BDNF.
The patterns of histone H3 acetylation in the BDNF exon I promoter on MS and ESC rats may be regulated by histone deacetylase (HDAC) expression. Specifically, rodent and human studies have found that HDAC5 is regulated by stress and antidepressant drugs. 49, [53] [54] [55] In a previous study, we investigated the effect of MS and ESC treatment on expression of HDAC5 in the hippocampus. 33 Hippocampal mRNA levels of HDAC5 were upregulated in MS rats, and this effect was prevented by chronic ESC. The regulation of expression of different classes of HDAC (class I to class IV) should be investigated in future studies.
We found no change in the levels of MeCP2 binding to the BDNF exon I promoter in MS rats, although our previous study showed that MeCP2 binding to the exon IV promoter was increased in rats after MS. Two previous studies have reported MeCP2 binding to the BDNF exon IV promoter in rat cortical neurons. 56, 57 These studies showed that MeCP2 binds specifically to the cyclic AMP response element (CRE) within the BDNF exon IV promoter and acts as a negative regulator of BDNF expression. 56 On the other hand, MeCP2 is rapidly released from the BDNF exon IV promoter through dissociation of the MeCP2/CRE-binding protein (CREB) complex following cortical neuronal activation, thereby facilitating BDNF transcription. 57 Although the role of MeCP2 in regulating the exon I promoter has not been investigated, activation of the BDNF exon I promoter requires CREB binding to CRE within the promoter. 58 Moreover, a previous study found more potential MeCP2 sites in the exon I promoter than in the exon IV promoter. 59 The MeCP2 sites are scattered throughout the exon I promoter, whereas they are confined to a small region in the exon IV promoter. Moreover, MeCP2 is released slowly from the exon I promoter following NMDA receptor activation. 59 These differences may partially explain the different effects of MS on MeCP2 binding to BDNF promoters in the hippocampus.
MeCP2 was originally identified as a transcriptional repressor that specifically binds to methylated DNA to induce gene silencing. However, several studies have suggested an additional role for MeCP2 as an activator of gene transcription in the ELSdependent epigenetic modification of hypothalamic tissue. 60 For example, a previous study in mice found that MS led to phosphorylation of MeCP2 and reduced MeCP2 binding to the AVP enhancer in the paraventricular nucleus of the hypothalamus. 31 This change was associated with low levels of DNA methylation and increased AVP expression, HPA axis activity, and depression-like behavior. 31, 61 Notably, the MeCP2 expression pattern was inconsistent with its binding pattern in specific promoters. Moreover, MeCP2 mRNA levels were significantly decreased in the medial prefrontal cortex of maltreated adult rats, 62 and MS has been shown to reduce the number of cells labeled by an MeCP2 antibody in the nucleus accumbens. 63 The effect of antidepressant drugs on MeCP2 expression has been widely investigated. A previous study found that treatment with fluoxetine for 10 days increased the number of cells expressing MeCP2 and MeCP2 mRNA in the adult rat brain, 64 suggesting that early intervention with antidepressant drugs can normalize MeCP2 expression in females with Rett syndrome, which is caused primarily by mutations in the MeCP2 gene. 65 Another study found that chronic imipramine treatment induced MeCP2 phosphorylation, which was necessary to prevent the depression-like behavior induced by chronic social defeat stress. 66 However, to date, our studies are the only investigations of the effects of antidepressant drugs on ELS-induced changes in MeCP2. We previously found that chronic ESC significantly decreased MeCP2 binding to the BDNF exon IV promoter in the hippocampus of adult rats subjected to MS, 33 which is consistent with our present finding of decreased MeCP2 binding to the exon I promoter. MeCP2 occupancy at BDNF promoters may be a novel target for intervention in individuals with ELS.
MS promotes change in the expression of DNMT1 and DNMT3a, which are representative of maintenance and de novo methyltransferase activity, respectively. Our findings are consistent with a previous study showing that MS (3 h daily from PND 1 to PND 10) increased DNMT activity in the hippocampus of adult rats. 67 Another study found an increase in DNMT1 expression in the dentate gyrusderived neural precursor cells of adult rats subjected to MS (3 h daily from PND 2 to PND 14). 68 Moreover, the authors reported that MS attenuated the neural differentiation of adult neural precursor cells, which was reversed by a DNMT inhibitor. Contrary to these findings, one study found that DNMT1 and DNMT3a mRNA levels were reduced in the medial prefrontal cortex of maltreated rats, 62 and another found no change in DNMT activity in the prefrontal cortex of MS rats. 67 It may be that the DNMT response to ELS is different in the hippocampus and prefrontal cortex.
Previous studies have shown that chronic mild stress increases the mRNA expression of DNMT1 and DNMT3a in the striatum of mice, and that DNMT inhibitors produce antidepressant-like effects on the behavior induced by chronic mild stress. 69 Specifically, the tricyclic antidepressant drugs, amitriptyline and imipramine, and the SSRI, paroxetine, reduced DNMT activity by targeting DNMT1. 70 ESC reversed hypermethylation of the p11 gene promoter in the prefrontal cortex of a genetic rat model of depression and reduced mRNA expression of DNMT1 and DNMT3a. 71 A more recent study found that the antipsychotic drug, quetiapine, reversed depression-like behavior and increased maternal deprivation-induced DNMT activity in the hippocampus. 67 We found that chronic ESC treatment clearly prevented the MS-induced decreases in DNMT1 and DNMT3a expression in the adult hippocampus. Our study, together with others, provides evidence supporting the hypothesis that antidepressant drugs may exert direct epigenetic effects. 72 The present study has a number of limitations. First, levels of DNA methylation in the BDNF exon I promoter were not examined. Instead of DNA methylation levels, we examined MeCP2 binding to methylated CpG sites using ChIP assays. Reduced MeCP2 occupancy causes an increase in BDNF expression, 56 but it is not known if reduced MeCP2 occupancy is associated with hypomethylation of the BDNF promoter. We observed a downregulation of DNMT expression in MS rats treated with ESC; however, it remains unclear if the recovery effect of ESC on BDNF expression mediated reduced DNMT expression. Therefore, additional DNA methylation studies are needed to examine the causal relationship. Second, the present study did not conduct behavioral tests. Previous studies have shown that MS induces depression-like behavior. 44, 73 Therefore, to strengthen the findings of the present study, future studies evaluating histone modification of the BDNF exon I promoter should include behavioral testing.
In conclusion, using our rodent model, we showed that exposure to MS during the third postnatal week elicits persistent changes in BDNF expression in adults via epigenetic regulation of the BDNF exon I promoter. Moreover, these MS-induced alterations can be prevented by treatment with antidepressant drugs during adulthood. The epigenetic mechanism of the BDNF gene is a potential target for the development of new antidepressant drugs.
